Drugs / RXIM002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07322718 | Dec 2025 → Dec 2027 expected | — | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RXIM002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07322718 ↗ |
| Modality | Other / unclassified | “circular RNA-mediated in-vivo CAR T-cell therapy” NCT07322718 ↗ |
| Route | Intravenous | “intravenous administration of RXIM002” NCT07322718 ↗ |
| Target | CD19 | “CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy” NCT07322718 ↗ |